An interventional study of VUNO Med®-Fundus AI™ in Diabetic Retinopathy (DR), Diabete Mellitus and Fundus Photography, sponsored by VUNO Inc.. Recruiting at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-04-13.
Sponsored by VUNO Inc. · Not applicable, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Diabetic Retinopathy with a site in Korea, Republic of — 2 open to participants now, 4 under way, none of them phase 3. Diabetic Retinopathy · Korea, Republic of.
Among the 14 studies in Diabetic Retinopathy with a site in Korea, Republic of, this one is the 2nd largest by planned enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2026, is one of 3 with no phase, and was the 14th registered.
783 studies on the registry are indexed under Diabetic Retinopathy; 145 are open to participants now.
Browse Diabetic Retinopathy studies →2 of the 14 studies in Diabetic Retinopathy with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Kyungpook National University Hospital · Sites in Korea, Republic of
Ages 20–80 · Healthy volunteers
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 93 Diabetic Retinopathy studies recruiting now, 61 (66%) set no upper age limit and 10 (11%) stop at 75 or younger; 8 take children under 18; 30 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 340 is above the median of 80 across 484 interventional studies indexed under Diabetic Retinopathy.
Median enrollment 49 across the 11 interventional studies, 206 across the 3 observational. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 14 have an industry lead sponsor. The 10 most frequent:
VUNO Inc. is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
VUNO Inc. has 1 study filed under Diabetic Retinopathy — fewer than ten, so there is no comparison to draw.
2 of the studies in Diabetic Retinopathy with a site in Korea, Republic of that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06770933Vantage Biosciences LtdA Study to Evaluate the Efficacy and Safety of Orally Administered VX-01 | 2027-07 |
| NCT07378956VUNO Inc.Clinical Efficacy of Implementing an AI-SaMD for Funduscopy Analysis in Patients With Diabetes Mellitus | 2027-08-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 14 studies in Diabetic Retinopathy with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this study is to investigate the efficacy of implementing the AI-SaMD(VUNO Med®-Fundus AI™) alongside routine clinical practice for the detection of diabetic retinopathy.
The primary objective of this study is to compare the true referral rate between patients with VUNO Med®-Fundus AI™-assisted screening (intervention group) and those receiving usual clinical care without AI assistance (control group) among patients with diabetes mellitus.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
For participants assigned to the intervention group, VUNO Med®-Fundus AI™ will be applied to the acquired fundus images, and the AI-generated outputs will be shown to clinicians during routine care.
Device: VUNO Med®-Fundus AI™
For participants assigned to the control group, fundus images will be interpreted according to usual clinical care without AI assistance.
VUNO Med®-Fundus AI™ is an artificial intelligence-based fundus image detection and diagnostic support software. The software automatically identifies abnormal retinal findings and provides information on the type and location of detected abnormalities to aid clinical decision-making.
True Referral Rate
The true referral rate is defined as the proportion of subjects who were diagnosed with diabetic retinopathy by an ophthalmologist among those referred to ophthalmology with suspected diabetic retinopathy. The true referral rate will be compared between the intervention and control groups.
Time frame: within 6 months
Diabetic Retinopathy (DR) Diagnosis Rate
Proportion of subjects diagnosed with diabetic retinopathy among all enrolled subjects will be compared between the intervention group and the control group.
Time frame: Within 6 months
Odds Ratio
Odds ratio between the diagnosis of diabetic retinopathy and the application of the AI system among subjects referred to ophthalmology will be calculated.
Time frame: Within 6 months
Referral Rate
Proportion of subjects referred to ophthalmology for suspected diabetic retinopathy among all enrolled subjects will be compared between the intervention group and the control group.
Time frame: Within 6 months
Time to Diabetic Retinopathy Diagnosis
Time interval from the diagnosis of diabetes mellitus to confirmed diagnosis of diabetic retinopathy based on ophthalmologic evaluation among referred subjects will be compared between the intervention group and the control group.
Time frame: Within 6 months
Performance of the AI System in Detecting Diabetic Retinopathy
Sensitivity, specificity, accuracy, positive predictive value (PPV), and negative predictive value (NPV) of the AI system will be calculated in comparison with ophthalmologist-confirmed diagnoses.
Time frame: Within 6 months
Accuracy of Referral for Diabetic Retinopathy
Proportion of subjects whose referral decisions (referral or non-referral) are concordant with ophthalmologist-confirmed DR status will be compared between the intervention group and the control group.
Time frame: Within 6 months
Adherence Rate
Proportion of referred subjects who attend an ophthalmology department will be compared between the intervention group and the control group.
Time frame: Within 6 months
Interim Analysis
One interim analysis will be conducted when 50% of subjects have completed all study visits. The purpose of this analysis is to review the status of subject dropouts and the reasons for dropout in each group. This procedure will be conducted by a statistician who is independent of the study conduct.
Time frame: Within 6 months
Plan to share: Yes — The institutional dataset used in this study, along with de-identified results, is available upon reasonable request for purposes such as systematic review or meta-analysis, only with approval from the corresponding author and the official approval of local IRB.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
No publications or documents are linked to this record.
Started Apr 2026 (actual). Primary completion is estimated for Aug 2027, 16 months after the start.
Of 126 interventional studies with no phase under Diabetic Retinopathy, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 60. This study's planned 16 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
VUNO Inc.